These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
44. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857 [TBL] [Abstract][Full Text] [Related]
45. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439 [TBL] [Abstract][Full Text] [Related]
46. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Sorbye H; Baudin E; Perren A Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724 [TBL] [Abstract][Full Text] [Related]
47. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102 [TBL] [Abstract][Full Text] [Related]
48. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms. Ohmoto A; Morizane C Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473 [TBL] [Abstract][Full Text] [Related]
49. A pilot study of the immune microenvironment of GI neuroendocrine carcinoma. McDonald A; Avadhani V; Oprea-Ilies G; Zakka K; Lesinski GB; Gbolahan OB; Alese O Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39045861 [TBL] [Abstract][Full Text] [Related]
50. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Cives M; Strosberg J Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921 [TBL] [Abstract][Full Text] [Related]
51. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Oberg K Curr Opin Endocrinol Diabetes Obes; 2009 Feb; 16(1):72-8. PubMed ID: 19115524 [TBL] [Abstract][Full Text] [Related]
52. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Mafficini A; Scarpa A Endocr Rev; 2019 Apr; 40(2):506-536. PubMed ID: 30657883 [TBL] [Abstract][Full Text] [Related]
53. Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That? Uccella S Endocr Pathol; 2024 Jun; 35(2):91-106. PubMed ID: 38470548 [TBL] [Abstract][Full Text] [Related]
54. The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors. Shida T; Furuya M; Kishimoto T; Nikaido T; Tanizawa T; Koda K; Oda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Nakatani Y; Miyazaki M Mod Pathol; 2008 Nov; 21(11):1363-70. PubMed ID: 18587321 [TBL] [Abstract][Full Text] [Related]
55. Highlights of the biology of endocrine tumours of the gut and pancreas. Rindi G; Bordi C Endocr Relat Cancer; 2003 Dec; 10(4):427-36. PubMed ID: 14713255 [TBL] [Abstract][Full Text] [Related]
57. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon. Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650 [TBL] [Abstract][Full Text] [Related]
58. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Klöppel G; Anlauf M; Perren A Endocr Pathol; 2007; 18(3):150-5. PubMed ID: 18058264 [TBL] [Abstract][Full Text] [Related]
59. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas. Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935 [TBL] [Abstract][Full Text] [Related]
60. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis. Simon B; Lubomierski N Ann N Y Acad Sci; 2004 Apr; 1014():284-99. PubMed ID: 15153447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]